A recent study reveals that individuals who stop using new slimming jabs like Mounjaro or Wegovy tend to recover reduced body mass much more quickly than those who halt traditional lifestyle plans.
Published data in a prominent medical journal shows that while obese people can lose substantial amounts of their total mass while using the jabs, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"People buying these medications need to be aware of the potential of fast weight regain when the medication ends," stated lead investigator Dr. Susan Jebb.
That rate of regain implies a reversion to starting weight in about a year and a half.
Weighing Treatments
The study, which examined 37 of studies involving thousands of participants, contrasted the effects of GLP-1 agonists with other pills.
The team point out that individuals who shed pounds through diet and exercise typically experience a more gradual creep back—around 0.1 kg a month—once they finish.
Explaining the Fast Regain
Nutrition scientists suggest the way of the jabs is key to understanding the accelerated rebound.
These medications copy a body's own chemical called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels far above than the body's typical production might result in the system to generate a reduced amount of its endogenous hormone, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement leads to hunger is no longer kept in check, making overeating a significant risk."
A Chronic Issue?
The NHS recommend the jabs for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Many experts say that, due to the high risk of relapse, the therapy might need to be life-long.
This opinion is supported by pharmaceutical companies, who note that the results "underscore the long-term nature of excess weight," similar to managing conditions like hypertension.
Patient Accounts
Individuals who have stopped the medication explain a powerful return of appetite.
"I experienced a switch activating and I was suddenly starving," described an individual.
The struggle is worsened if users have not established lasting lifestyle or habit changes during treatment.
Widespread Adoption
Survey data show that a significant number of adults in the UK have tried these injections in the past year, with demand being substantial.
- Use is more common among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the medications through private healthcare rather than public health services.
In conclusion, clinicians caution that while these medications are potent agents for shedding pounds, they are not a standalone cure and lasting health benefits likely depends on combined lifestyle changes.
